Prolongation of GLP-1 Adherence When Using Continuous Glucose Monitoring
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 800 (estimated)
- Sponsor
- Abbott Diabetes Care · Industry
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThis study is to see if the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) will help prolong the length of time people with diabetes maintain adherence to glucagon-like peptide 1 (GLP-1/GIP) agonists.
Loading trial locations…